Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

CLICK HERE FOR CME CREDIT

Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division
Department of Medicine
Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
Medical Director, Stanford Medical Center Transfer Center,
Stanford Univer